oral MEK1/2 inhibitor - Novartis Institutes for BioMedical Research

oral MEK1/2 inhibitor

Preclinical, oncology

from HTS and SBDD

J. Med. Chem.

Novartis Institutes for BioMedical Research

Context. MAP855 (Novartis Institutes for BioMedical Research) is an oral MEK1/2 active-site inhibitor. Several MEK inhibitors (e.g. cobimetinib, trametinib) have been approved for cancer, generally derived from the same…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.